E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers R > Headlines for RPI 2019 Intermediate Finance Trust > News item
Published on 8/19/2020 in the Prospect News Bank Loan Daily and Prospect News Investment Grade Daily.

S&P rates Royalty Pharma notes BBB-

S&P said it assigned its BBB- issue-level rating to Royalty Pharma plc's proposed unsecured notes which will be issued in multiple tranches.

“We view the transaction as leverage neutral because the company will use the proceeds to repay debt at RPI 2019 Intermediate Finance Trust. Royalty Pharma, which recently completed its IPO, is the parent of RPI 2019 Intermediate Finance Trust,” S&P said in a press release.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.